Structured evidence table for Resistant Starch Supplementation Gut Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Resistant Starch Supplementation Gut Health Randomized Trial | Mounting evidence shows that RS consumption may reduce systemic inflammation and improve insulin sensitivity, glucose metabolism, and gut function (). | 4 | Piperni Elisa (2026) | Resistant starch types 2 and 4 induce distinct and reversible changes in the human gut microbiome |
| Resistant Starch Supplementation Gut Health Randomized Trial | For instance, RS2 is commonly associated with an increase in starch-degrading Firmicutes, notably the keystone species(,), and butyrate producers like(). | 4 | Piperni Elisa (2026) | Resistant starch types 2 and 4 induce distinct and reversible changes in the human gut microbiome |
| Resistant Starch Supplementation Gut Health Randomized Trial | Therefore, a comprehensive, high-resolution characterization of how different RS types influence both microbiome composition and functional capacity is still needed to ultimately achieve the knowledge required to design precision nutrition protocols that recommend the dietary fiber sources providing the greatest beneficial impact on an individual basis. | 4 | Piperni Elisa (2026) | Resistant starch types 2 and 4 induce distinct and reversible changes in the human gut microbiome |
| Resistant Starch Supplementation Gut Health Randomized Trial | 1 2 3 4 5 6 7 8 9 – 12 13 14 Diet is a major determinant of human physiology and gut microbiome composition and functional capacity (). | 4 | Piperni Elisa (2026) | Resistant starch types 2 and 4 induce distinct and reversible changes in the human gut microbiome |
| Resistant Starch Supplementation Gut Health Randomized Trial | Background Menopause-associated estrogen decline promotes gut dysbiosis and impaired gut health, but the effects of resistant starch (RS) under estrogen-deficient conditions remain unclear. | 4 | Olawale F (2026) | Resistant Starch Supplementation Modulates Gut Microbiota, Short-Chain Fatty Acids, and Markers of Gut Barrier Integrity in Estrogen-Deficient Mice. |
| Resistant Starch Supplementation Gut Health Randomized Trial | Data were analyzed using a 2-way analysis of variance with estrogen status and diet as factors, followed by post hoc tests when P Results RS supplementation induced distinct clustering in bacterial β -diversity, enriched beneficial genera including Bifidobacterium, Dubosiella, Bacteroides, and Akkermansia, and reduced proinflammatory Clostridium sensu_stricto_1 in estrogen-deficient mice. | 4 | Olawale F (2026) | Resistant Starch Supplementation Modulates Gut Microbiota, Short-Chain Fatty Acids, and Markers of Gut Barrier Integrity in Estrogen-Deficient Mice. |
| Resistant Starch Supplementation Gut Health Randomized Trial | Both RS3 and RS4 enhanced Tjp1 and Cldn1 expression and elevated fecal SCFAs, whereas RS3 additionally increased Reg3g expression. | 4 | Olawale F (2026) | Resistant Starch Supplementation Modulates Gut Microbiota, Short-Chain Fatty Acids, and Markers of Gut Barrier Integrity in Estrogen-Deficient Mice. |
| Resistant Starch Supplementation Gut Health Randomized Trial | Objectives Herein, we examine the effects of retrograded (RS3) and chemically modified (RS4) RS on the gut microbiota and gut barrier integrity in estrogen-deficient mice. | 4 | Olawale F (2026) | Resistant Starch Supplementation Modulates Gut Microbiota, Short-Chain Fatty Acids, and Markers of Gut Barrier Integrity in Estrogen-Deficient Mice. |
Source documents